Spruce Biosciences (NASDAQ:SPRB) and Adagene (NASDAQ:ADAG) Financial Contrast

Adagene (NASDAQ:ADAGGet Free Report) and Spruce Biosciences (NASDAQ:SPRBGet Free Report) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, earnings, dividends, risk, valuation, institutional ownership and analyst recommendations.

Analyst Recommendations

This is a breakdown of current ratings and price targets for Adagene and Spruce Biosciences, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Adagene 0 0 1 0 3.00
Spruce Biosciences 0 6 2 0 2.25

Adagene presently has a consensus price target of $5.00, indicating a potential upside of 76.68%. Spruce Biosciences has a consensus price target of $5.00, indicating a potential upside of 774.58%. Given Spruce Biosciences’ higher probable upside, analysts clearly believe Spruce Biosciences is more favorable than Adagene.

Institutional and Insider Ownership

9.5% of Adagene shares are owned by institutional investors. Comparatively, 91.7% of Spruce Biosciences shares are owned by institutional investors. 21.2% of Adagene shares are owned by insiders. Comparatively, 9.1% of Spruce Biosciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Profitability

This table compares Adagene and Spruce Biosciences’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Adagene N/A N/A N/A
Spruce Biosciences -461.67% -57.53% -43.45%

Risk and Volatility

Adagene has a beta of 0.65, suggesting that its stock price is 35% less volatile than the S&P 500. Comparatively, Spruce Biosciences has a beta of 2.41, suggesting that its stock price is 141% more volatile than the S&P 500.

Valuation & Earnings

This table compares Adagene and Spruce Biosciences’ gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Adagene $18.11 million 6.90 -$18.95 million N/A N/A
Spruce Biosciences $10.09 million 2.33 -$47.92 million ($1.13) -0.51

Adagene has higher revenue and earnings than Spruce Biosciences.

Summary

Adagene beats Spruce Biosciences on 8 of the 12 factors compared between the two stocks.

About Adagene

(Get Free Report)

Adagene Inc., a clinical stage biotechnology company, engages in the research, development, and production of monoclonal antibody drugs for cancers. The company's product candidates include ADG106, a human ligand-blocking agonistic anti- CD137 IgG4 monoclonal antibodies (mAbs) that is in Phase 1b/2 clinical trials for the treatment advanced solid tumors and non-Hodgkin's lymphoma; ADG126, a masked fully-human anti-CTLA-4 mAb that is in Phase 1 clinical trial for the treatment advanced/metastatic solid tumors; and ADG116, a human ligand-blocking anti-CTLA-4 mAb, which is in Phase 1b/2 clinical development for the treatment of advanced/metastatic solid tumors. It also offers ADG104, an anti-PD-L1 mAb that is in Phase 2 clinical development; ADG125, a novel anti-CSF-1R mAb, which is in Phase I clinical trial; ADG206, a masked, Fc engineered anti-CD137 agonistic POWERbody; ADG153, a masked anti-CD47 IgG1 SAFEbody, which is in preclinical for the treatment hematologic and solid tumors; ADG138, novel HER2xCD3 POWERbody, which is in preclinical for the treatment HER2-expressing solid tumors; and ADG152, a v POWERbody, which is in preclinical stage for the treatment off-tumor toxicities, as well as develops anti-CD28 bispecific POWERbody TCEs. The company was incorporated in 2011 and is headquartered in Suzhou, China.

About Spruce Biosciences

(Get Free Report)

Spruce Biosciences, Inc., a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders. The company engages in developing tildacerfont, a non-steroidal therapy to enhance disease control and reduce steroid burden for patients suffering from congenital adrenal hyperplasia (CAH), which is in Phase 2b clinical trial; and to evaluate glucocorticoid reduction in adult patients with classic CAH that is Phase 2b clinical trial. It is also developing tildacerfont for the treatment of pediatric classic congenital adrenal hyperplasia in children that is in Phase 2 clinical trial; and for females with polycystic ovary syndrome, which is in Phase 2 clinical trial. Spruce Biosciences, Inc. has a license agreement with Eli Lilly and Company to research, develop, and commercialize compounds for various pharmaceutical uses; and collaboration and license agreement with Kaken Pharmaceutical Co. Ltd. to develop, manufacture, and commercialize tildacerfont for the treatment of CAH in Japan. The company was incorporated in 2014 and is headquartered in South San Francisco, California.

Receive News & Ratings for Adagene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adagene and related companies with MarketBeat.com's FREE daily email newsletter.